RxDoctor Payments Data

Ashritha Penagaluri, MD

Clinical Cardiac Electrophysiology · Shreveport, LANPI 1285999318

Payments from drug & device makers

What this record shows

This record is dominated by grants: $17,833 of the $25,524 with a category attached, or 69.9%. 21 manufacturers reported payments, led by Medtronic at 39.9% of the total. Reporting peaked in 2020 at $18,151 and has fallen 83.6% since, to $2,979 in 2025.

$25,524in general payments, 2019–2025

Across 136 payments — averaging $187.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$10K
  • Boston Scientific$7K
  • Abbott$5K
  • Biosense Webster, Inc.$1K
  • Medical Device Business Services, Inc.$941
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$489
  • plus $692 from 15 others

What the payments were for

  • Grants$17,83370%
  • Travel & lodging$4,51718%
  • Food & beverage$2,89311%
  • Education$2811%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$25,524 in reported general payments places this provider in the 55th percentile of 43 clinical cardiac electrophysiology providers in Louisiana.

See all clinical cardiac electrophysiology providers in Louisiana

Medicare billing

Part B allowed, 2024
$47,599
Medicare patients
248
Services billed
612

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban135$107,538
Metoprolol Succinate134$1,343
Propafenone Hcl ErPropafenone Hcl12$1,019
Flecainide Acetate31$807
Dofetilide20$802
Amiodarone Hcl24$211
Metoprolol Tartrate38$129
Carvedilol29$127
Amlodipine Besylate17$58
Furosemide22$13

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$64$107,538135 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 43 clinical cardiac electrophysiology providers in Louisiana.

Other clinical cardiac electrophysiology in Shreveport

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →